Articles tagged with Glioblastomas
Researchers developed a mass spectrometry method to analyze tissue during brain tumor surgery, distinguishing glioma from non-tumor tissue with high confidence. The method, which takes roughly three minutes, provides actionable molecular information during surgery, potentially guiding treatment decisions and improving patient outcomes.
Researchers are exploring biomarker-guided patient selection and combination therapies to overcome glioblastoma's biological barriers. Agents targeting tumor metabolism, immunotherapies, and oncolytic viruses are being investigated.
Researchers developed an AI approach to predict glioblastoma recurrence, allowing for targeted treatments before the cancer becomes visible on MRI. The tool uses microscopic images of fresh, unprocessed tissue and scored based on tumor infiltration, with an accuracy of predicting recurrence within 5-10 millimeters of the sampled tissue.
Researchers explored strategies to restore MHC-I expression in CNS cancers to make them more visible to the immune system. Approaches include epigenetic therapies, AAV vectors, PCSK9 inhibition, and modifying the tumor microenvironment. However, efficient delivery, antigen processing, and a limited neoantigen repertoire remain signific...
Mayo Clinic researchers have identified a potential new approach to treating glioblastoma by reprogramming immune cells and boosting chemotherapy response. Inhibiting the enzymatic activity of MALT1 protein can shift immune cells from a protective state to one that promotes an antitumor immune response.
A new study shows that administering cell immunotherapy before surgery to remove a brain tumour is significantly more effective than administering it afterwards. CAR-T cells were able to neutralize tumor cells and immune suppression, leading to unprecedented durable tumour control.
The researcher will investigate how infected cells live and die, and what chemical signals they release to surrounding cells. This work could lead to better antiviral drugs and virus-based cancer treatments.
Researchers have discovered lymph node-like structures in the skull bone marrow of mice that act as rapid first responders against brain cancer and neurodegenerative diseases. The discovery offers a new way to fight brain cancer and other neurological diseases.
A Korean research team developed a patient-specific blood-brain tumor barrier-on-a-chip model to predict individual responses to glioblastoma therapies. The chip recreates a patient's own tumor cells together with the surrounding peritumoral vascular environment, allowing for precise predictions of treatment responses.
Recent research explores the use of nanomaterial-based drug delivery to increase treatment efficacy for glioblastoma, a type of brain tumor with poor prognosis. Stimuli-responsive and biomimetic nanomedicines are designed to overcome the blood–brain barrier and deliver drugs selectively within tumors.
A NIH-funded research project has generated a comprehensive collection of patient-derived tumor models, covering 25 types of cancer from thousands of donor tissues. These models closely match their parental tumors in terms of genetic alterations and gene expression signatures, enabling researchers to explore tumor evolution and diversity.
Researchers have developed a 'double-punch' approach to treating brain cancer using light-activated nanoparticles that enable precise imaging during surgery and targeted phototherapy after surgery. The platform has shown promising results in mouse models, achieving 100% survival rate at 60 days.
Researchers from Virginia Commonwealth University have uncovered a protein, TRNAU1AP, that helps glioblastoma cells survive and multiply. Targeting this protein could make cancer cells more vulnerable to treatment, potentially leading to improved survival rates.
Research reveals CUDC-907's therapeutic potential in combating glioblastoma by inhibiting PI3K and HDAC, leading to enhanced TMZ sensitivity through disrupted double-strand break repair pathways.
Scientists at UVA have developed a new method to target glioblastoma, the most common and deadly brain cancer, by delivering microRNAs through the brain's natural barrier. The approach shows promise in slowing tumor growth and extending survival in animal models.
Sylvester researchers develop AI-powered fracture prediction models, train as wildland firefighters to reduce cancer risk, and discover new targets for pancreatic cancer treatment. A new tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells.
Researchers identify a promising new strategy to overcome drug resistance in deadly brain cancer by blocking nitrosative stress. Combining BA-101 with temozolomide slows tumor growth, reduces cancer's ability to spread, and increases cancer cell death.
A new UAB trial demonstrates promising results for a novel immunotherapy in treating glioblastoma. The treatment, DeltEx DRI, has been shown to more than double progression-free survival, with median overall survival reaching up to 19.5 months.
Researchers developed a strategy to attack glioblastoma on two fronts by targeting the tumour and its immune support system. In preclinical models, the therapy eliminated detectable tumours and led to long-term disease-free survival.
Researchers propose protein coronas as a dynamic navigation interface to shape how nanomedicines are recognized and delivered across the blood-brain barrier. The corona can be manipulated to bias circulation, targeting ligands, and intracellular trafficking for improved brain delivery.
Researchers have developed a novel treatment technique using sugar-coated nanoparticles to target and destroy glioblastoma cells. The method overcomes two major obstacles in glioblastoma treatment: delivering therapeutic agents through the blood-brain barrier and targeting tumors preferentially.
Researchers identified a critical biological difference in glioblastoma development between male and female laboratory models, pinpointing an immune pathway fueled by GABA in females. Blocking this signal improves outcomes in women, but not men.
Christina Tringides, an assistant professor at Rice University, has won the Pew Biomedical Scholar award to explore how glioblastoma grows and spreads into healthy tissue. Her research aims to develop personalized therapies for brain cancer by mimicking the brain's extracellular matrix.
The Sylvester Cancer Institute has made significant breakthroughs in multiple myeloma treatment with the immunotherapy drug teclistamab, which extends remission and survival rates. Additionally, research has shed light on glioma evolution after treatment and identified genetic markers for aggressive solitary fibrous tumors.
Researchers at UCLA Jonsson Comprehensive Cancer Center have been awarded a $3.2 million NIH grant to develop advanced imaging and surgical strategies for improving glioblastoma outcomes. The team aims to use pH-based imaging to guide precise tumor removal and explore targeted therapies that target the tumor's acid-regulating systems.
A University of Ottawa-led study has discovered a hidden network driving glioblastoma's aggressive growth, highlighting a promising target for next-generation therapies. The research reveals that a protein called OSMR plays a critical role in tumor progression and supports the survival of brain tumour stem cells.
Researchers developed a nanofiber drug delivery system that uses electrospun fiber membranes to deliver multiple drugs in concert, demonstrating improved efficacy against glioblastoma. The system enables localized long-term delivery of drugs directly at the tumor site after surgery.
A new study reveals that nitrosylcobalamin, a vitamin B12 analog, selectively crosses the blood-brain barrier and targets glioblastoma tissue, demonstrating broad antitumor activity. The therapy also shows synergistic activity with existing treatments, offering a promising new strategy for treating this deadly brain cancer.
Researchers from ECOG-ACRIN Cancer Research Group will present updated outcomes from the STAMP study on Merkel cell carcinoma, primary results from studies in glioblastoma and non-small cell lung cancer, and emerging approaches in precision oncology. AI-driven insights from the TAILORx breast cancer trial will also be showcased.
A new cytokine-armored CAR-T cell therapy has been developed to attack aggressive brain tumors in mice while reducing side effects. The approach recruits the body's immune system using IL-12 and DR-18 proteins, strengthening the anti-cancer response and improving tumor control.
A personalized vaccine has been shown to be safe and effective in treating glioblastoma, a fast-growing brain cancer. The vaccine elicited robust and broad immune responses that appeared to increase recurrence-free survival in patients after surgery.
Glioblastoma is a highly aggressive brain tumor that has seen modest improvements in survival rates over the past decade. Researchers at UCLA's Jonsson Comprehensive Cancer Center are part of a national effort to develop more personalized approaches to care, combining advanced imaging and analysis of tumor tissue samples and blood test...
A NIH-funded study discovered that testosterone may play a key role in limiting brain tumor growth in men by suppressing inflammation and stress hormone production. Analysis of over 1,300 men with glioblastoma found that supplemental testosterone was significantly associated with improved survival rates.
Dr. Aparna Bhaduri receives $750k Pershing Square Sohn Cancer Prize for her innovative glioblastoma research. Her advanced human organoid models reveal how tumors interact with the immune system and brain cells, driving tumor aggressiveness.
Hyperbaric oxygen therapy (HBOT) exhibits dual effects in glioblastoma management, enhancing radiosensitivity and chemotherapy efficacy while promoting tumor progression. HBOT normalizes the tumor microenvironment via vessel normalization and immune cell modulation, attenuating cancer stem cell properties.
Researchers discovered a powerful molecule called miR-181d that weaks tumors and helps the immune system fight back against glioblastoma. The study found that tumors in 'exceptional responders' contain higher levels of miR-181d, which blocks cancer cells' ability to repair DNA damage.
Researchers at DZNE discovered complex, situation-dependent interactions between glioblastoma cells and microglia in the brain. The study found that microglial activity changes as tumors spread, influencing containment and spread of the disease.
Researchers discovered that neuronal nitric oxide synthase drives neuroblastoma through the mTOR signaling cascade. Treating cancer cells with a selective inhibitor called BA-101 collapsed tumor growth in mice with striking force, and silencing the nNOS gene also led to significant results.
Researchers at Mayo Clinic have developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors, improving survival rates in preclinical models of glioblastoma. The approach uses small lipid-based particles to target tumor cells and enhance the impact of radiation therapy.
Researchers at Adelaide University identified CD47 as a critical mechanism driving glioblastoma growth and spread. The study found that removing or blocking CD47 reduced tumour cell proliferation, migration, and invasion, leading to improved survival times in animal models.
Recent discoveries have shed light on gene expression control in tumor growth, revealing the critical role of epigenetic marks and genomic imprinting. The findings have significant implications for cancer treatment, as they suggest that disrupting the tumor's access to neural signaling may halt its growth.
Blocking two key 'don't eat me signals' in cancer cells heightens the immune response and sensitizes tumors to immunotherapy in glioblastoma models. Researchers found that simultaneously blocking CD47 and CD24 improved immunotherapy response, allowing macrophages to better recognize and attack cancer cells.
Researchers developed magnetically controlled microrobots made from diatoms to target glioblastoma lesions with photodynamic therapy. The microrobots achieved a significant cytotoxic effect on primary glioblastoma cells and demonstrated good biocompatibility.
The novel approach outperforms standard CAR-T cell therapy in preclinical studies using mouse models of glioblastoma and ovarian cancer. Armored CAR-T cells eliminate tumors, reshape the tumor environment, and boost immune-cell activity.
Approximately 40 cancer patients will receive LMP744 for five consecutive days, with biological analyses conducted on brain tissues before and after treatment. If results are favorable, treatment will continue for 12 cycles to evaluate parameters such as progression-free survival and overall survival.
PhD candidate Michael Gomes is developing advanced nanoscale drug carriers to deliver chemotherapy more effectively to brain tumours. His research focuses on polydopamine nanoparticles and the glymphatic system to reach tumours directly, potentially increasing drug concentrations and reducing toxic effects.
A single injection of an oncolytic virus recruits immune cells to penetrate and persist deep within brain tumors, inducing long-term infiltration of immune T cells. This therapy expands pre-existing T cells in the brain, leading to a therapeutic benefit for patients with glioblastoma.
Researchers identified a previously unrecognized metabolic defence mechanism in aggressive brain tumours: a sugar-rich shield that protects tumour cells from ferroptosis. The study found that the sugar shield and lipid droplet storage mechanisms cooperate to evade cell death.
Researchers identified blood-based biomarkers that can help distinguish patients with glioblastoma who are most likely to live longer from novel treatment with an engineered oncolytic virus. The study found that adding an immune booster increased survival times and improved immunological fitness.
Researchers have identified three unique subtypes of mismatch repair deficient high-grade gliomas, providing a clearer understanding of their development and behavior. The findings are helping guide more precise therapies and offer hope for a potential vaccine to target cancer cells earlier.
A UCalgary study found that adding high doses of vitamin B3 to the treatment plan may help rejuvenate compromised immune cells to kill tumour cells. The clinical trial showed promising results, with 82% of participants free of cancer progression at six-months.
Researchers at the University of Virginia Health System have identified a molecule that blocks the gene responsible for glioblastoma, a fast-growing and deadly brain cancer. The compound shows promise in preventing the invasive cancer from spreading through the brain without causing harm to healthy tissue.
Researchers at the University of Cincinnati Cancer Center are developing a new treatment for glioblastoma, a highly aggressive brain cancer. The team is using 'glioblastoma-on-a-chip' technology and wafer delivery to stimulate the immune system and improve patient outcomes.
Researchers review EMT mechanisms and its impact on GBM progression, highlighting key signaling pathways and GSCs. EMT-targeted therapies offer promising strategies to disrupt tumor growth and enhance immune responses.
Cancer cells tap into the nervous system's power grid by forming synaptic contacts with nerve cells, promoting tumor growth and spread. Venkataramani's research aims to repurpose the drug perampanel for glioblastoma treatment and develop gene therapy approaches to disconnect tumors from the nervous system.
Researchers developed miniature 3D tumor organoid models that closely mimic the human brain, revealing how glioblastoma interacts with surrounding brain cells and immune system. The models identified PTPRZ1 as a key regulator of tumor behavior, which helps determine its aggressiveness.
Researchers developed a new method to identify effective treatment combinations for glioblastoma by analyzing individual cell types and their gene expression signatures. This approach has the potential to personalize cancer treatment and may be useful for other cancers and diseases.
Researchers developed a new diagnostic chip that can detect tumor cells in blood, allowing for real-time monitoring of brain cancer treatment effectiveness. The GlioExoChip uses extracellular vesicles to assess treatment response, providing a quick and minimally invasive way to inform doctors about chemotherapy efficacy.
Researchers discovered glioblastoma cells use PRDM9 to survive chemotherapy and regrow tumors. By blocking PRDM9 or cutting off cholesterol supply, persister cells can be wiped out, improving survival in mice. This breakthrough offers new strategies for treating the deadliest brain cancer.
Researchers at the University of Plymouth investigate why drugs used to treat other tumours are ineffective against NF2-related schwannoma and meningioma tumours. They explore repurposing clinically tested cancer drugs to target MDR mechanisms, which may lead to effective therapies for patients with these tumours.